Clinical trials: OligoProgressive Metastatic Disease
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response.
- Trial name
- IOSCAR (NCT04624828)
- Testing
- Radiotherapy, androgen deprivation therapy (ADT), immune evaluation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Clinico Humanitas
Metastatic Renal Cell Carcinoma, Radiotherapy
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases occur in half of RCC patients. Management of metastatic RCC is based on systemic treatments (targeted therapies/immunotherapy).
- Trial name
- GETUG-StORM-01 (NCT04299646)
- Testing
- Steretactic radiotherapy
- Where
- 30 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Francois Baclesse
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT06260033
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing…
- Trial name
- PSMA-OLIGO-PRO (NCT07691697)
- Testing
- Comprehensive Progression-Directed Radiotherapy
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
- Trial name
- NCT04070209
- Testing
- Darolutamide (BAY1841788), SBRT
- Where
- 11 sites in Canada
- Volunteers
- 66 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well it works in determining treatment response for patients with stage IV…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07619599
- Testing
- Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options…
- Conditions
- Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
- Trial name
- BOSS (NCT06055881)
- Testing
- Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy…
- Trial name
- SECURE (NCT06927635)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Systemic therapy
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
OligoProgressive Metastatic Disease
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation [the removal or destruction of a body part or tissue or its function], or embolization [a…
- Trial name
- NCT06367972
- Testing
- Local Consolidation Therapy, Next-line Systemic Therapy
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancer, Oligoprogressive
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin…
- Trial name
- SUPPRESS (NCT04989725)
- Testing
- Standard arm, Experimental arm
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
OligoProgressive Metastatic Disease
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3…
- Trial name
- NCT06925984
- Testing
- SBRT
- Where
- 5 sites in Belgium
- Volunteers
- 48 people
- Sponsor
- Jules Bordet Institute
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing…
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Oligoprogressive, Progression
- Trial name
- NCT04974671
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Non-small Cell Lung Cancer
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if…
- Trial name
- CURB2 (NCT06686771)
- Testing
- SBRT, First or second-line standard of care therapy
- Where
- 75 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Melanoma, OligoProgressive Metastatic Disease
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients…
- Trial name
- CURB-Melanoma (NCT07112170)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Oligoprogressive, Castration-Resistant Prostate Cancer
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases.
- Trial name
- NCT04838899
- Testing
- Stereotactic Body Radiation Therapy (SABR)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute